Synthetic cyclin dependent kinase inhibitors - New generation of potent anti-cancer drugs

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 341-353

  Hajdúch, Marián ^a   Havlíèek, Libor ^b   Veselỳ, Jaroslav ^c   Novotnỳ, Radko ^c   Mihàl, Vladimìr ^a   Strnad, Miroslav ^d  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d Institute of Experimental Botany   (Czech Republic)

Author keywords

Butyrolactone I; Cell cycle; Cyclin dependent kinase; Flavopiridol; Olomoucine; Roscovitine

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR; FLAVONOID; FLAVOPIRIDOL; PIPERIDINE DERIVATIVE;

CELL CULTURE; CELL TRANSFORMATION; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASES; DRUG DESIGN; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; PIPERIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0032605463     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_37     Document Type: Article

References (58)

1. Strauss, M., LukàŠ, J., Bàrtek, J.: Unrestricted cell cycling and cancer. Nature Med. 1995, 1, 1245-1246
2. Bàrtek, J., Lukàa, J., Strauss M.: A common pathway to tumor growth: deregulation of Rb-dependent restriction point control (Review). Oncol. Rep., 1996,3,237-240.
3. Levine A., J., Momand, J., Finlay, C.A.: The p53 tumour supressor gene. Nature, 1991,351,453-456
4. Hollstein, M, Sidransky, D., Vogelstein, B., Harris, C.C.: p53 mutations in human cancers. Science, 1991, 253,49-53.
5. Gartel, A.L., Serfas M.S., Tyner, A.L.: p21 - Negative regulator of the cell cycle. P.S.E.M.B., 1996, 213, 138-149
6. El-Deiry, W.S., Harper, J.W., O'Connor, P.M.: WAF1/CIP1 is induced in p53-mediated Gl arrest and apoptosis. Cancer Res., 1994, 54, 1169-1174
7. Grana, X., Reddy, E.P.: Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CDKls). Blood, 1995, 11, 211-219
8. Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R., Beach, D.: p21 is a universal inhibitor of cyclin kinases. Nature, 1993, 336, 701-704
9. Luo, Y, Hurwitz, J., Massague, J.: Cell-cycle inhibition by independent CDK and PCNA binding domains in p21cipl. Nature, 1995, 375, 159-161
10. Waldman, T., Lengauer, C., Bunz, F., Kinzler, K., Vogelstein, B.: The role of p21 in cell cycle control and drug sensitivity. Cell Cycle Therapeutics. The Conference held on November 6-7, 1997. Washington, DC, USA.
11. Book of Abstracts. Published by International Business Communications (225 Turnpike Road, Southborough, MA 01772-1749, USA)
12. Solomon, J.M., Harper, J.W., Shuttleworth, J.: CAK, the p34 cdc2 activating kinase, contains a protein identical or closely related to p40MO15. EMBO J., 1993, 12, 3133-3142
13. Pines J., Hunter, T.: Cyclin-dependent kinases: an embarrassment of riches. In: Hames, B.D., Glover, D.M. (Eds.): Cell cycle control, Oxford University Press, New York, 1997, 144-176
14. Taubert, H., Meye, A., Wurl, P.: Prognosis is associated with p53 mutation type foe soft tissue sarcoma patients. Cancer Res., 1996, 56, 4134-4136
15. Strang, P., Nordstrom, B., Nilsson, S., Bergstrom R., Tribukait, B.: Mutant p53 protein as a predictor of survival in endometrial carcinoma. Eur. J. Cancer, 32A, 598-602
16. Asgari, K., Sesterhenn, I.A., McLeod, D.G., Cowan, K., Moul J.W., Seth, P., Srivastava, S.: Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. Int. J. Cancer, 1997, 71, 377-382
17. INK4CDKN2 andp53 genes cooperate to induce apoptotic tumor cell death. Nature Med., 1997, 3, 313-319
18. Selivanova, G., lotsova, V., Okan, I., Fritsche, M., Strom, M., Groner, B., Graftstrom, R.C., Wiman, K.G.: Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med., 1997, 3, 632-638
19. WAFI. Curr. Biol., 1996, 7, 71-80
20. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells (correlation with decreased HI kinase activity). Biochem. Pharmacol., 1993, 46, 1831-1840
21. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, Ch., Czech, J., Naik, R., Sausville, E.: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst., 1992, 84, 1736-1740
22. Losiewicz, M.D., Carlson, B.A., Kaur, G., Sausville, E.A., Worland, P.J.: Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun., 1994, 201, 589-595
23. Webster, K.: Targeting the cell cycle. In: Cell Cycle Therapeutics. The Conference held on November 6-7, 1997, Washington, DC, USA.
24. Book of Abstracts. Published by International Business Communications (225 Turnpike Road, Southborough, MA 01772-1749, USA)
25. Sausville, E.: Flavopiridol and UCN-OI: Cell cycle modulators in clinical trial. In: Cell Cycle Therapeutics. The Conference held on November 6-7, 1997, Washington, DC, USA.
26. Book of Abstracts. Published by International Business Communications (225 Turnpike Road, Southborough, MA 01772-1749, USA)
27. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK 4 in human breast carcinoma cells. Cancer Res., 1996, 56, 2973-2978
28. Parker, B.W., Kaur, G., Nieves-Neira, W., Taimi, M., Kolhagen, G., Shimizu, T., Losiewicz, M.D., Pommier, Y, Sausville, E.A., Senderowicz, A.M.: Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 1998, 91, 458-465
29. Azevedo (Jr.), W.F., Mueller-Dieckmann, H.J., Schulze-Gahmen, U., Worland, P.J., Sausville, E., Kim, S.H.: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci., 1996, 93, 2735-2740
30. Christian, M.C., Pluda, J.M., Ho, P.T.C., Arbuck, S.G., Murgo, A.J. and Sausville, E.A.: Promising new agents under development by the division of cancer treatment, diagnosis, and centers of the National Cancer Institute. Semin. Oncol., 1997, 2, 219-240
31. Kitagawa, M., Okabe, T., Ogino, H., Matsumoto, H., Suzuki-Takahashi, I., Kokubo, T., Higashi, H., Saitoh, S., Taya, Y., Yasuda, H., Ohba, Y., Nishimura, S., Tanaka, N., Okuyama, A.: Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene, 1993, 8, 2425-2432
32. Someya, A., Tanaka, N., Okuyama, A.: Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts. Biochem. Biophys. Res. Commun., 1994, 198, 536-545
33. Nishio K., Ishida, T., Arioka, H., Kurokawa, H., Fukuoka, K., Nomoto, T., Fukumoto, H., Yokote, H., Saijo, N.: Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res., 1996, 16, 3387-3395
34. Kitagawa, M., Higashi, H., Suzuki-Takahashi, I., Okabe, T., Ogino, H., Taya, Y, Nishimura, S., Okuyama, A.: A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene, 1994, 9, 2549-2557
35. Skoog, F., Armstrong, D.J.:Cytokinins. Annu. Rev.Plant Physiol., 1970, 21, 359-384
36. Shaw, G.: Chemistry of adenine cytokinins. In: Mok, D.W.S., Mok, M.C. (Eds): Cytokinins, Chemistry, Activity and Function, 15-34, CRC Press, Boca Raton
37. McGaw, B. A., Burch, L. R.: Cytokinin biosynthesis and metabolism. In: Davies, P.J. (Ed.): Plant Hormones, Physiology, Biochemistry and Molecular Biology, 98-117. Kluwer Academic Publishers, Dordrecht
38. Sprinzl, M., Dank, N., Nock, S., Schon, A.: Compilation of tRNA sequences and sequences of tRNA genes. Nucl. Acid. Res. 9, 2127-2171
39. 6-(2-isopcntenyl)adenosine, a natural component of mammalian transfer RNA. Cancer Res. 1970, 30, 1429-1439
40. 6-Substituted adenine derivatives as growth inhibitors of human leukemic myeloblasts and S-180 cells. Proc. Am. Assoc. Cancer Res. 1967, 8, 23-27
41. Gallo, R.C., Whang-Peng, J., Perry, S.: Isopentenyl-adenosine stimulates and inhibits mitosis of lymphocytes treated with phytohemagglutinin. Science 1969, 165, 400-402
42. 2-isopentenyl)adenosine (iPA). Proc. Am. Assoc. Cancer, Res., 1968, 9, 69-74
43. Jones, R., Grace, J.T., Mittelman, A., and Woodruff, M.W.: Human pharmacology and initial clinical trail of isopentenyl adenosine (iPA). Proc. Am. Assoc. Cancer Res., 1968, 9, 35
44. Mittelman, A., Evans, J.T., Chheda, G.B.: Cytokinins as chemotherapeutic agents. Ann. N. Y. Acad. Sci., 1972, 15, 225-23
45. Veselý, J., Havlíèek, L., Strnad, M., Blow, J.J., Donella.Deana, A., Pinna, L., Letham, D.S., Kato, J., Detivaud, L., Leclerc, S., Meijer, L.: Inhibition of cyclin-dependent kinases by purine analoques. Eur. J. Biochem., 1994, 224, 771-786
46. Parker, C.W., Wilson, M., Letham, D.S., Cowley, D.E., MacLeod, J.K.: Inhibitors of two new enzymes which metabolize cytokinins. Phytochem.,1986, 25, 303-310
47. Norbury, C, Nurse, P.: Animal cell cycles and their control. Ann. Rev. Biochem., 1992, 61, 444-470
48. Meijer, L., Borgne, A., Mulner, O., Chong, J.P.J., Blow, J.J., Inagaki, N., Inagaki, M., Delcros J.-G., Moulinoux, J.-P.: Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem., 1997, 243, 527-536
49. Schulze-Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D.O., Meijer, L., Vesely, J., Kim, S.-H.: Multiple modes of ligand recognition: Crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins: Structure, function, and genetics, 1995, 22, 378-391
50. De Azavedo, W.F., Leclerc, S., Meijer, L., Havlíèek, L., Strnad, M., Kim, S.-H.: Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem., 1997, 243, 518-526
51. Havlíèek, L., Hanuš, J., Veselý, J., Leclerc, S., Meijer, L., Shaw, G., Strnad, M.: Cytokinin-derived cyclindependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem., 1997,40, 1997, 408-412
52. Abraham, R.T., Acquarone, M., Andersen, A., Asensi, A., Belle, R., Berger, F., Bergounioux, C., Brunn, G., Buquet-Fagot, C., Fagot, D., Glab, N., Goudeau, H., Goudeau, M., Guerrier, P., Houghton, P., Hendriks, H., Kloareg, B., Lippai, M., Marie, D., Maro, B., Meijer, L., Mester, J., Mulner-Lorillon, O., Poulet, S.A., Schierenberg, E., Schutte, B., Vaulot, D., Verlhac, M.H.: Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol. Cell, 1995, 83, 105-120
53. Schutte B., Nieland L., van Engeland M., Henfling M. E. R., Meijer L., Ramaekers C. S.: The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp. Cell Res., 1998, 236, 4-15
54. Hajdúch M., Nosková V, Havlíèek L., Feketová G., Gojová L., Michálek T., Novotný R., Kryštof V., Kotala V., Veselý J., Strnad M., Mihál V.: Olomoucine-derived synthetic cdk inhibitors: the mechanism of apoptotic death of tumor cells and in vivo antitumor activity. In: In: Cell Cycle Therapeutics. The Conference held on November 6-7, 1997, Washington, DC, USA.
55. Book of Abstracts. Published by International Business Communications (225 Turnpike Road, Southborough, MA 01772-1749, USA)
56. Ongkeko, W., Ferguson, D.J.P., Harris, A.L., Norbury, C.: Inactivation of cdc2 increases the level of apoptosis induced by DNA damage. J. Cell Sci., 1995, 108, 2897-2904
57. Markus, M.A., Kahle, P.J., Winkler, A., Hortsmann, S., Anneser, J.M., Borasio, G.D.: Survival-promoting activity of inhibitors of cyclin-dependent kinases on primary neurons correlates with inhibition of c-Jun kinase-1. Neurobiol. Dis., 1997, 4, 122-133
58. Hajdúch, M., Koláo, Z. Novotný, R., Hanuš. J., Mihál, V, Hlobilková, A., Nosková, V., Strnad, M.: Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucin. Anti-Cancer Drugs, 1997, 8, 1007-1013